KR101417237B1 - Ｐｄｅ9 억제제로서 사용되는 아미노-헤테로환식 화합물 - Google Patents
Ｐｄｅ9 억제제로서 사용되는 아미노-헤테로환식 화합물 Download PDFInfo
- Publication number
- KR101417237B1 KR101417237B1 KR1020117019758A KR20117019758A KR101417237B1 KR 101417237 B1 KR101417237 B1 KR 101417237B1 KR 1020117019758 A KR1020117019758 A KR 1020117019758A KR 20117019758 A KR20117019758 A KR 20117019758A KR 101417237 B1 KR101417237 B1 KR 101417237B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrimidin
- dihydro
- pyrazolo
- ethyl
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C(*(c1ccccc1)(c1ccccc1)c1ccccc1)c1ncccn1 Chemical compound C(*(c1ccccc1)(c1ccccc1)c1ccccc1)c1ncccn1 0.000 description 2
- IMRWILPUOVGIMU-UHFFFAOYSA-N Brc1ccccn1 Chemical compound Brc1ccccn1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- UTALBSXROBFNSI-UHFFFAOYSA-N C(C1CNC1)c1ncccn1 Chemical compound C(C1CNC1)c1ncccn1 UTALBSXROBFNSI-UHFFFAOYSA-N 0.000 description 1
- QQMCPYJKGBZIMO-UHFFFAOYSA-N C1NCC1Oc1ncccc1 Chemical compound C1NCC1Oc1ncccc1 QQMCPYJKGBZIMO-UHFFFAOYSA-N 0.000 description 1
- OIOVGEQVQGJYAB-UHFFFAOYSA-O CC(C(N1)=NC([NH2+]C2CCCC2)=C(C=N)C1=O)OS(C)(=O)=O Chemical compound CC(C(N1)=NC([NH2+]C2CCCC2)=C(C=N)C1=O)OS(C)(=O)=O OIOVGEQVQGJYAB-UHFFFAOYSA-O 0.000 description 1
- ABLTZWIYELNTQQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1=Cc1ncccn1)=O Chemical compound CC(C)(C)OC(N(C1)CC1=Cc1ncccn1)=O ABLTZWIYELNTQQ-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1=O)=O VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- XRRXRQJQQKMFBC-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1O)=O Chemical compound CC(C)(C)OC(N(C1)CC1O)=O XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 1
- IRIHNITYXPTXEL-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc1ncccc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc1ncccc1)=O IRIHNITYXPTXEL-UHFFFAOYSA-N 0.000 description 1
- JVPHQWFZAXEBMJ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc1ncccn1)O Chemical compound CC(C)(C)OC(N(C1)CC1Oc1ncccn1)O JVPHQWFZAXEBMJ-UHFFFAOYSA-N 0.000 description 1
- MSVZMUILYMLJCF-UHFFFAOYSA-N CS(OC(C1)CN1C(c1ccccc1)c1ccccc1)(=O)=O Chemical compound CS(OC(C1)CN1C(c1ccccc1)c1ccccc1)(=O)=O MSVZMUILYMLJCF-UHFFFAOYSA-N 0.000 description 1
- MSFVEEFXECBJPG-UHFFFAOYSA-N ClCc1ncccn1 Chemical compound ClCc1ncccn1 MSFVEEFXECBJPG-UHFFFAOYSA-N 0.000 description 1
- BHELLAOXDCZWRB-UHFFFAOYSA-N Fc1cc(OC(C2)CN2C(c2ccccc2)c2ccccc2)ccc1 Chemical compound Fc1cc(OC(C2)CN2C(c2ccccc2)c2ccccc2)ccc1 BHELLAOXDCZWRB-UHFFFAOYSA-N 0.000 description 1
- FZIITHAOPCRHAB-UHFFFAOYSA-N Fc1cccc(OC2CNC2)c1 Chemical compound Fc1cccc(OC2CNC2)c1 FZIITHAOPCRHAB-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N Oc1cc(F)ccc1 Chemical compound Oc1cc(F)ccc1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20609209P | 2009-01-26 | 2009-01-26 | |
| US61/206,092 | 2009-01-26 | ||
| PCT/IB2010/050133 WO2010084438A1 (en) | 2009-01-26 | 2010-01-13 | Amino-heterocyclic compounds used as pde9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110108415A KR20110108415A (ko) | 2011-10-05 |
| KR101417237B1 true KR101417237B1 (ko) | 2014-07-08 |
Family
ID=42062324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117019758A Expired - Fee Related KR101417237B1 (ko) | 2009-01-26 | 2010-01-13 | Ｐｄｅ9 억제제로서 사용되는 아미노-헤테로환식 화합물 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8278295B2 (enExample) |
| EP (1) | EP2389382B1 (enExample) |
| JP (1) | JP5656874B2 (enExample) |
| KR (1) | KR101417237B1 (enExample) |
| CN (1) | CN102292340B (enExample) |
| AR (1) | AR074966A1 (enExample) |
| AU (1) | AU2010207507B2 (enExample) |
| CA (1) | CA2748864C (enExample) |
| DK (1) | DK2389382T3 (enExample) |
| ES (1) | ES2420860T3 (enExample) |
| HR (1) | HRP20130530T1 (enExample) |
| IL (2) | IL213923A (enExample) |
| MX (1) | MX2011007862A (enExample) |
| PL (1) | PL2389382T3 (enExample) |
| PT (1) | PT2389382E (enExample) |
| SG (1) | SG172805A1 (enExample) |
| SI (1) | SI2389382T1 (enExample) |
| TW (1) | TWI404721B (enExample) |
| UY (1) | UY32391A (enExample) |
| WO (1) | WO2010084438A1 (enExample) |
| ZA (1) | ZA201105931B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| CA2744278C (en) | 2008-11-19 | 2015-09-08 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| WO2012033101A1 (ja) | 2010-09-07 | 2012-03-15 | アステラス製薬株式会社 | キノキサリン化合物 |
| EP2615089B1 (en) | 2010-09-07 | 2016-04-27 | Astellas Pharma Inc. | Pyrazoloquinoline compounds |
| CN106905324B (zh) | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| HK1199879A1 (en) | 2012-01-26 | 2015-07-24 | H.隆德贝克有限公司 | Pde9 inhibitors with imidazo triazinone backbone |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
| CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
| WO2015171753A1 (en) * | 2014-05-06 | 2015-11-12 | Visco Anthony G | Methods of treating or preventing preterm labor |
| CA2954098A1 (en) * | 2014-08-27 | 2016-03-03 | F. Hoffmann-La Roche Ag | Substituted azetidine derivatives as taar ligands |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| HRP20210543T1 (hr) | 2015-07-07 | 2021-05-14 | H. Lundbeck A/S | Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti |
| US10370336B2 (en) | 2015-07-29 | 2019-08-06 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone PDE9 inhibitors |
| US10370337B2 (en) | 2015-07-29 | 2019-08-06 | Merck, Sharp & Dohme Corp. | Oxy-cyanoquinolinone PDE9 inhibitors |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017048720A1 (en) | 2015-09-15 | 2017-03-23 | Praxis Biosciences, Llc | Prodrugs of fencamfamine |
| CN105467028A (zh) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法 |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| TN2018000383A1 (en) | 2016-07-06 | 2020-06-15 | H Lundbeck As | Pde9 inhibitors for treatment of peripheral diseases. |
| EP3529250B1 (en) * | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| PT3532064T (pt) | 2016-10-28 | 2020-09-03 | H Lundbeck As | Tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos |
| WO2018091687A1 (en) | 2016-11-18 | 2018-05-24 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| WO2018125810A1 (en) | 2016-12-28 | 2018-07-05 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as pde2 inhibitors |
| CA3051976A1 (en) * | 2017-02-23 | 2018-08-30 | Boehringer Ingelheim International Gmbh | New medical use of compound iii |
| CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法 |
| CN110621676B (zh) * | 2017-05-22 | 2024-02-09 | 托帕杜制药公司 | 可溶性鸟苷酸环化酶激活剂和磷酸二酯酶抑制剂的双重作用模式及其用途 |
| MA48793A (fr) | 2017-05-26 | 2020-04-08 | Imara Inc | Procédés de fabrication et d'utilisation d'inhibiteurs de pde9 |
| CA3060183A1 (en) * | 2017-06-01 | 2018-12-06 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| CN110612102A (zh) | 2017-06-01 | 2019-12-24 | 卫材R&D管理有限公司 | 含有吡唑并喹啉衍生物的路易氏体病治疗剂 |
| SG11201909359YA (en) | 2017-06-01 | 2019-11-28 | Eisai R&D Man Co Ltd | Pharmaceutical composition comprising pde9 inhibitor |
| IL270395B (en) * | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| RU2019144010A (ru) | 2017-06-08 | 2021-07-13 | Мерк Шарп И Доум Корп. | Пиразолопиримидиновые ингибиторы pde9 |
| CN111655695B (zh) | 2017-11-27 | 2025-05-27 | 达特神经科学有限公司 | 作为pde1抑制剂的取代的呋喃并嘧啶化合物 |
| JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク． | ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態 |
| EP3843737A4 (en) | 2018-08-31 | 2022-06-01 | Imara Inc. | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE |
| TWI816026B (zh) * | 2019-03-08 | 2023-09-21 | 大陸商藥捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制劑的用途和藥盒 |
| JP2022542421A (ja) * | 2019-07-29 | 2022-10-03 | コンステレーション・ファーマシューティカルズ・インコーポレイテッド | 神経障害の治療に使用するための化合物 |
| JP2025538452A (ja) * | 2022-11-15 | 2025-11-28 | フリーダム・バイオサイエンシズ，インコーポレーテッド | ９型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強 |
| WO2025040569A1 (en) * | 2023-08-18 | 2025-02-27 | Katholieke Universiteit Leuven | 1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and/or autoimmune diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037889A1 (en) | 2001-11-02 | 2003-05-08 | Astrazeneca Ab | Compounds and method for the treatment of overactive bladder |
| WO2008139293A1 (en) | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2009121919A1 (en) | 2008-04-02 | 2009-10-08 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| AU2002363960B2 (en) * | 2001-12-06 | 2008-07-10 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
-
2009
- 2009-12-31 TW TW098146481A patent/TWI404721B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 MX MX2011007862A patent/MX2011007862A/es active IP Right Grant
- 2010-01-13 HR HRP20130530AT patent/HRP20130530T1/hr unknown
- 2010-01-13 ES ES10701921T patent/ES2420860T3/es active Active
- 2010-01-13 WO PCT/IB2010/050133 patent/WO2010084438A1/en not_active Ceased
- 2010-01-13 SI SI201030250T patent/SI2389382T1/sl unknown
- 2010-01-13 JP JP2011547011A patent/JP5656874B2/ja not_active Expired - Fee Related
- 2010-01-13 SG SG2011047594A patent/SG172805A1/en unknown
- 2010-01-13 DK DK10701921.8T patent/DK2389382T3/da active
- 2010-01-13 AU AU2010207507A patent/AU2010207507B2/en not_active Ceased
- 2010-01-13 PT PT107019218T patent/PT2389382E/pt unknown
- 2010-01-13 CN CN201080005394.XA patent/CN102292340B/zh not_active Expired - Fee Related
- 2010-01-13 PL PL10701921T patent/PL2389382T3/pl unknown
- 2010-01-13 CA CA2748864A patent/CA2748864C/en not_active Expired - Fee Related
- 2010-01-13 EP EP10701921.8A patent/EP2389382B1/en not_active Not-in-force
- 2010-01-13 KR KR1020117019758A patent/KR101417237B1/ko not_active Expired - Fee Related
- 2010-01-25 AR ARP100100153A patent/AR074966A1/es unknown
- 2010-01-25 UY UY0001032391A patent/UY32391A/es not_active Application Discontinuation
- 2010-01-26 US US12/693,480 patent/US8278295B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 IL IL213923A patent/IL213923A/en not_active IP Right Cessation
- 2011-08-12 ZA ZA2011/05931A patent/ZA201105931B/en unknown
-
2012
- 2012-08-31 US US13/600,522 patent/US8618117B2/en not_active Expired - Fee Related
-
2013
- 2013-11-27 US US14/091,404 patent/US20140088081A1/en not_active Abandoned
-
2016
- 2016-07-21 IL IL246882A patent/IL246882A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037889A1 (en) | 2001-11-02 | 2003-05-08 | Astrazeneca Ab | Compounds and method for the treatment of overactive bladder |
| WO2008139293A1 (en) | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
| WO2009121919A1 (en) | 2008-04-02 | 2009-10-08 | Boehringer Ingelheim International Gmbh | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101417237B1 (ko) | Ｐｄｅ9 억제제로서 사용되는 아미노-헤테로환식 화합물 | |
| EP2152712B1 (en) | Amino-heterocyclic compounds | |
| AU2011226819B2 (en) | Amino-heterocyclic compounds | |
| HK1163092B (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
| HK1142595B (en) | Amino-heterocyclic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20170702 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20170702 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |